Financial Advisor | Financial Planners

Financial Planning

480-836-2326

  • Home
  • About Susan Linkous
    • Mission Statement
    • Susan’s Corner
    • Industry Awards
  • Services
  • Blog
  • Financial Reviews
  • Legal Docs
  • Contact Us
  • Account Login
You are here: Home / Blog / BIOTECHNOLOGY – “Susan On Money” for the Week of May 25, 2011

BIOTECHNOLOGY – “Susan On Money” for the Week of May 25, 2011

May 24 By Linkous Group

BIOTECHNOLOGY

By definition, biotechnology is a field of science that draws on the biological sciences such as microbiology, molecular biology and genetics. Many investments in this sector are measured against the NASDAQ Biotechnology Index. This index is comprised of companies listed on the NASDAQ and are classified as either biotech or pharmaceutical firms. The index is calculated under a modified capitalization-weighted methodology.

Investing in this sector can be risky and is most appropriate for growth-oriented investors with a long time horizon. The risks of loss of principal and volatility may be offset as “The potential for strong growth from new products for unmet medical needs, good pipelines, increasing profitability, and consolidation points to an exciting future for the biotechnology industry.” ~Rajiv Kaul.

To gain a better understanding of what a biotech firm looks like, here are a few that belong to the aforementioned index. This is not a recommendation to buy and is intended solely as educational material.

Amgen, Inc. (AMGN) – discovers, develops, manufactures, and delivers human therapeutics based on advanced in cellular and molecular biology.

Vertex Pharmaceuticals, Inc. (VRTX) – development and commercialization of small molecular drugs for the treatment of serious diseases worldwide.

Exelixis, Inc. (EXEL) – engages in the discovery, development, and commercialization of drugs for the treatment of cancer, metabolic, and cardiovascular disorders.

Jazz Pharmaceuticals (JAZZ) – a specialty pharmaceutical company that develops products for neurology and psychiatry in the U.S.

Each sector in the investment universe tells a compelling story and I can’t help but to be fascinated by the advancements in biotechnology. Please keep in mind that because of their narrow focus, sector investing will be subject to greater volatility than investing more broadly across many sectors and companies.

Until next week,

Susan R. Linkous

“Susan On Money”

Securities offered through LPL Financial

Member FINRA and SIPC

Filed Under: Blog

Search

Contact Us

    Your Name (required)

    Your Email (required)

    Your Phone

    Your Message

    captcha

    Verification (type 4 digit code shown above)

    Blog Archives

    • May 2022
    • April 2022
    • March 2022
    • January 2022
    • November 2021
    • March 2021
    • December 2020
    • March 2020
    • February 2020
    • January 2020
    • February 2019
    • October 2017
    • May 2017
    • March 2017
    • December 2016
    • October 2016
    • June 2016
    • May 2016
    • March 2016
    • January 2016
    • December 2015
    • November 2015
    • September 2015
    • July 2015
    • June 2015
    • May 2015
    • April 2015
    • March 2015
    • February 2015
    • January 2015
    • December 2014
    • November 2014
    • September 2014
    • August 2014
    • July 2014
    • June 2014
    • May 2014
    • April 2014
    • March 2014
    • February 2014
    • January 2014
    • December 2013
    • November 2013
    • October 2013
    • September 2013
    • August 2013
    • July 2013
    • June 2013
    • May 2013
    • April 2013
    • March 2013
    • February 2013
    • January 2013
    • December 2012
    • November 2012
    • October 2012
    • September 2012
    • August 2012
    • July 2012
    • June 2012
    • May 2012
    • April 2012
    • March 2012
    • February 2012
    • January 2012
    • December 2011
    • November 2011
    • October 2011
    • September 2011
    • August 2011
    • July 2011
    • June 2011
    • May 2011
    • April 2011
    • March 2011
    • February 2011
    • January 2011
    • December 2010
    • November 2010
    • October 2010

    Copyright © 2022

    The Linkous Group, Ltd. is a Registered Investment Advisor. Advisory services are only offered to clients or prospective clients where The Linkous Group, Ltd. and its representatives are properly licensed or exempt from licensure. This website is solely for informational purposes. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital. No advice may be rendered by The Linkous Group, Ltd. unless a client service agreement is in place.

    Check out your broker with BrokerCheck ,  Susan Linkous, CRD #2938653 brokercheck_logo-new